Spots Global Cancer Trial Database for larynx
Every month we try and update this database with for larynx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions | NCT03214835 | Laryngeal Disea... Laryngeal Tumor Laryngopharynge... | Endo CDx Brush ... | 18 Years - | CDx Diagnostics | |
| CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions | NCT03214835 | Laryngeal Disea... Laryngeal Tumor Laryngopharynge... | Endo CDx Brush ... | 18 Years - | CDx Diagnostics | |
| Pembrolizumab in Combination With CRT for LA-SCCHN | NCT02586207 | Head and Neck C... Squamous Cell C... Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer Laryngeal Cance... | pembrolizumab (... Cisplatin Radiation | 18 Years - | Sanford Health | |
| Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers | NCT00580203 | Head and Neck C... | - | Memorial Sloan Kettering Cancer Center | ||
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer | NCT03162731 | Larynx Lip, Oral Cavit... | Nivolumab Ipilimumab Simultaneous-In... Volume Modulate... | 18 Years - | Thomas Jefferson University | |
| Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer | NCT00094081 | Head and Neck N... | tirapazamine (S... cisplatin Radiation Thera... | 18 Years - | Sanofi | |
| The Head and Neck Tumor Biobank | NCT01644786 | Head and Neck S... | 18 Years - | Maastricht Radiation Oncology | ||
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer | NCT01087970 | Head and Neck N... | Pemetrexed Cetuximab Carboplatin Cisplatin | 18 Years - | Eli Lilly and Company | |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer | NCT01185171 | Head and Neck C... | ZD 1839 500mg | 18 Years - | University of Chicago | |
| CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions | NCT03214835 | Laryngeal Disea... Laryngeal Tumor Laryngopharynge... | Endo CDx Brush ... | 18 Years - | CDx Diagnostics | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN | NCT02126969 | Head and Neck C... Larynx | Low dose fracti... Docetaxel and C... | 18 Years - | University of Kentucky | |
| Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan | NCT02017288 | Head and Neck N... | 21 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | NCT02158234 | Squamous Cell C... | Cisplatin Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03238365 | Lip, Oral Cavit... Larynx | Nivolumab Tadalafil Therapeutic Con... | 18 Years - | Thomas Jefferson University | |
| Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer | NCT03109873 | Larynx Lip Oral Cavity Pharynx | External Beam R... Metformin Hydro... Placebo | 18 Years - 90 Years | Thomas Jefferson University | |
| A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures | NCT02262247 | OSA Oral Disease Oropharyngeal N... Hypopharyngeal ... | 22 Years - | Medrobotics Corporation | ||
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer | NCT02892487 | Cancer of Head ... | Swallowing ther... | 18 Years - | Rennes University Hospital | |
| Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer | NCT01843673 | Head and Neck C... | computed tomogr... cone-beam compu... radiography radiography radiography electronic port... image-guided ad... | 21 Years - | Virginia Commonwealth University | |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | NCT02158234 | Squamous Cell C... | Cisplatin Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer | NCT01089803 | Squamous Cell C... Laryngeal Cance... | 18 Years - | University of Minnesota | ||
| Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer | NCT01187472 | Head and Neck C... | 59 Years - | University of Chicago | ||
| Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | NCT03076281 | Larynx LIP Oral Cavity Pharynx | Metformin Hydro... Doxycycline Metformin +Doxy... | 18 Years - | Thomas Jefferson University | |
| Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN | NCT01884259 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... | Docetaxel Cisplatin 5-fluorouracil Cetuximab Induc... Cetuximab Radio... Boost irradiati... | 18 Years - 75 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer | NCT01057589 | Head and Neck N... | Pemetrexed Cetuximab Cisplatin Folic Acid Vitamin B12 | 18 Years - | Eli Lilly and Company | |
| Phase II Trial of Allovectin-7® for Head and Neck Cancer | NCT00050388 | Head and Neck C... Squamous Cell C... Head and Neck N... Carcinoma of th... | Allovectin-7® | 18 Years - | Vical | |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT01427205 | Head and Neck C... | Cetuximab OSI-906 Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer | NCT01187472 | Head and Neck C... | 59 Years - | University of Chicago | ||
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma | NCT00198328 | Head Neck Cance... | Medpulser Elect... Surgical Excisi... | 18 Years - | Inovio Pharmaceuticals | |
| Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | NCT03076281 | Larynx LIP Oral Cavity Pharynx | Metformin Hydro... Doxycycline Metformin +Doxy... | 18 Years - | Thomas Jefferson University | |
| The Head and Neck Tumor Biobank | NCT01644786 | Head and Neck S... | 18 Years - | Maastricht Radiation Oncology | ||
| Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer | NCT01326923 | Head and Neck S... | Cetuximab | 18 Years - | Louisiana State University Health Sciences Center Shreveport | |
| A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma | NCT01185158 | Head and Neck C... | ZD1839 (IRESSA) | 18 Years - | University of Chicago | |
| CONFIRM: Magnetic Resonance Guided Radiation Therapy | NCT04368702 | Gastric Cancer Invasive Breast... in Situ Breast ... Mantle Cell Lym... Larynx Cancer Bladder Cancer | Viewray MRIdian... | 18 Years - | Dana-Farber Cancer Institute | |
| Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | NCT00101582 | Mucositis Solid Tumors Stomatitis Head and Neck C... Squamous Cell C... | Placebo palifermin cisplatin chemo... Radiotherapy | 18 Years - | Swedish Orphan Biovitrum | |
| Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck | NCT01287390 | Primary Non-ope... Primary Non-ope... Primary Non-ope... Primary Non-ope... | video fluorosco... extra imaging scoring acute t... scoring of late... scoring quality... | 18 Years - | University Hospital, Ghent | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer | NCT02892487 | Cancer of Head ... | Swallowing ther... | 18 Years - | Rennes University Hospital | |
| Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer | NCT00094081 | Head and Neck N... | tirapazamine (S... cisplatin Radiation Thera... | 18 Years - | Sanofi | |
| Symptom Burden in Head and Neck Cancer | NCT01219673 | Head And Neck C... | Placebo Armodafinil Minocycline Bupropion | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| Interventional Study Collecting Quantitative and Qualitative Data About Patient With Non Treated Cancer | NCT01647477 | Upper Aerodiges... | interview questionnaires | 18 Years - | Centre Oscar Lambret | |
| Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | NCT03854032 | Lip Oral Cavity Squ... Pharynx Larynx Squamous Cell C... | Nivolumab IDO1 Inhibitor ... Therapeutic Con... Questionnaire A... | 18 Years - | Thomas Jefferson University | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers | NCT00580203 | Head and Neck C... | - | Memorial Sloan Kettering Cancer Center | ||
| Bilateral Elective Neck Dissection in Salvage Total Laryngectomy | NCT05746780 | Neck Cancer Larynx Larynx Cancer Neck | Elective bilate... | 18 Years - 90 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer | NCT01057589 | Head and Neck N... | Pemetrexed Cetuximab Cisplatin Folic Acid Vitamin B12 | 18 Years - | Eli Lilly and Company | |
| A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma | NCT01185158 | Head and Neck C... | ZD1839 (IRESSA) | 18 Years - | University of Chicago | |
| Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | NCT03529422 | Larynx Lip Oral Cancer Digestive Organ... | Durvalumab Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Vocal Cord vs Whole Laryngeal Radiotherapy for T1aN0 Glottic Cancer | NCT05679856 | Larynx Cancer S... Glottic Carcino... | Hypofractionate... Whole laryngeal... | 18 Years - | National Cancer Institute, Egypt | |
| Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer | NCT01089803 | Squamous Cell C... Laryngeal Cance... | 18 Years - | University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
